While this study is the first to assess the relationship between ESA dose and sEpoR level among CKD patients, one previous study which measured sEpoR levels in patients with liver and kidney disease [28] reported elevated sEpoR levels in the plasma of five hemodialysis patients on EPO when compared to healthy controls. This evidence concerns the gene EPO and chronic kidney disease.